Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918580 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
NCT00918580 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 158 participants.
The verdict
NCT00918580, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
Study Summary
This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine. The study will measure the amount of antibodies (the proteins that fight off germs) produced by children with Sickle Cell Disease after they have been given the 13-valent pneumococcal vaccine between 6 and less than 18 years of age. They will be given the vaccination twice, each vaccination separated by approximately 6 months.
Interventions
- BIOLOGICAL 13-valent Pneumoccocal Conjugate Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918580
The ClinicalTrials.gov registry entry for NCT00918580 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 13-valent Pneumoccocal Conjugate Vaccine is the first listed.
NCT00918580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00918580 about?
NCT00918580 is a clinical study titled "Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease". This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine. The study will measure the amount of antibodies (the proteins that fight off ...
What is the current status of trial NCT00918580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2009-11. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00918580?
The interventions under investigation include: 13-valent Pneumoccocal Conjugate Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00918580?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.